A pharmaceutical executive fainted in the Oval Office during President Trump's announcement of a new weight-loss drug deal.

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and ...

Discover Donald Trump's revolutionary initiative to reduce the cost of obesity drugs to as low as $149, making weight loss ...

GLP-1 medications like Ozempic, Wegovy and Zepbound have become some of the most in-demand prescriptions in the country, helping people lose weight and improve their overall health. But many say the ...

A pharmaceutical company boss collapsed behind US President Donald Trump during a White House announcement about a ...

Donald Trump has outed White House communications chief and resident attack dog Steven Cheung as a user of “fat drugs.” ...

Eli Lilly CEO David Ricks, one of the key participants at the event, was speaking when the man who is reportedly a ...

The Health and Human Services Secretary was called out for appearing to "flee the scene" and "skedaddle" as others in the ...

Dow Jones Top Company Headlines at 11 PM ET: OpenAI CEO Says U.S. Shouldn't Bail Out AI Companies | Blackstone ... The comments come after OpenAI's chief financial officer discussed the role of ...

Get the latest news and live updates as the government shutdown enters Day 37, with FAA cuts to flights and energy bill assistance cuts looming.

A new deal with major drugmakers, unveiled by U.S. President Donald Trump on Thursday, aims to expand coverage and cut prices for popular weight-loss drugs south of the border.